GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sunmax Biotechnology Co 4728.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

392.00

—

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Sunmax Biotechnology Co

Its shares trade on Taipei Exchange under the ticker 4728.TWO. It has been listed since 25 January 2010. In the fiscal year to 31 December 2025, it reported revenue of TWD 2.03bn and net income of TWD 725.7m. At that date it held total assets of TWD 2.12bn and shareholders' equity of TWD 1.62bn.

SunMax Biotechnology Co., Ltd. engages in the development, manufacture, and commercialization of medical devices, biomedical material and bio surgical products. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-01-25. The firm's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The firm distributes its products principally in Taiwan, Mainland China and other regions.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 Jan 2010
Employees
37

Leadership

Pay as last reported

  • Qiguo LinChairman of the Board, Chief Executive Officer, since 2019
  • Yanji YangVice Chairman of the Board, since 2022
  • Mr. Mingyi LinGeneral Manager, since 2019
  • Meixing GuoDeputy General Manager-Administration, since 2022
  • Mr. Guangheng LinExecutive Deputy General Manager, since 2019
  • Mr. Yude LinDeputy General Manager-Technology Division
  • Mr. Chunqiang ZhangDeputy General Manager-Administration
  • Jiazhen CaiCorporate Governance Officer
  • Shixing ZhuangHead of Finance & Accounting
  • Mr. Canghai ChenDirector
  • Mr. Chao-Lung ChenDirector
  • Fangying ChenDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company is headquartered in Tainan, Taiwan
  • Offers a range of medical devices and biomedical products
  • Products are applied in both medical and beauty care industries

Weaknesses

  • Limited to a small employee count of 37
  • Products distributed primarily in Taiwan and Mainland China
  • IPO date is 2010-01-25, indicating a long-standing operation

Opportunities

  • Expansion into other regions beyond Taiwan and Mainland China
  • Growth potential in medical and beauty care industries
  • Development of new products in biomedical field

Threats

  • Dependence on limited geographic markets
  • Competition in the biotechnology sector
  • Reliance on existing product lines without mention of innovation

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.